This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -60.87% and -57.78%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is Sangamo Therapeutics (SGMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SGMO) Outperforming Other Medical Stocks This Year?
How to Find Strong Stocks Under $10 to Buy During the Market Comeback
by Benjamin Rains
Today we screened for strong "cheap" stocks that are trading under $10 a share that investors might want to buy amid the market comeback...
Will Sangamo Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Sangamo Therapeutics.
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
by Zacks Equity Research
The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.
Sangamo Therapeutics (SGMO) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of 112.90% and 222.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Files BLA for Gene Therapy to Treat Hemophilia A
by Zacks Equity Research
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
by Ekta Bagri
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session
by Zacks Equity Research
Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A
by Zacks Equity Research
BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of 27.27% and 56.70%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of 25.71% and -9.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss
by Zacks Equity Research
BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
by Zacks Equity Research
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study
by Zacks Equity Research
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
BioMarin (BMRN) to File for Hemophilia A Candidate in Q4
by Zacks Equity Research
BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.
Implied Volatility Surging for Sangamo (SGMO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sangamo (SGMO) stock based on the movements in the options market lately.
Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -51.85% and -70.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
For Sangamo's (SGMO) Q1, investor focus will be on its gene therapy candidate, SB-525, currently under evaluation for hemophilia A. The company also boasts several other early-stage promising candidates in its pipeline.
Sangamo Rises on Positive Phase I/II Hemophilia Study Data
by Zacks Equity Research
Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Analysts Estimate Sangamo Therapeutics (SGMO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Sangamo (SGMO) This Earnings Season?
by Zacks Equity Research
On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.